Table 1 National recommendations
From: Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
Recommendation | Online publication date | Print publication date | Recommended screening practice |
|---|---|---|---|
1FDA Dear Healthcare Professional Letter | 7/12/2004 | Online only | Screen patients at high risk of HBV infection before initiation of rituximab therapy. Closely monitor carriers of HBV for clinical and laboratory signs of active HBV infection and for signs of hepatitis during and for up to several months after rituximab therapy. |
2AASLD | 1/26/2007 | 2/2007 | Screen patients at high risk for HBV infection prior to immunosuppressive therapy. |
Test with HBsAg. | |||
3CDC | 9/19/2008 | 9/19/2008 | Screen all patients prior to immunosuppressive therapies. |
Test with HBsAg, anti-HBc, and anti-HBs. | |||
4AASLD Update | 7/28/2009 | 9/2009 | Screen patients at high risk for HBV infection prior to immunosuppressive therapy. |
Test with HBsAg and anti-HBc. | |||
5NCCN | 8/28/2009 | Online only | Screen cancer patients with lymphoid malignancies, patients who have spent significant time in HBV-endemic areas or have risk factors for HBV infection, and patients anticipating intensive immunosuppressive therapy. |
Test with HBsAg, anti-HBc, and anti-HBs. | |||
6IOM | 1/11/2010 | 1/11/2010 | Screen patients with HBV risk factors. |
Test with HBsAg. | |||
7ASCO | 6/1/2010 | 7/1/2010 | Screen cancer patients at high risk for HBV infection or anticipating highly immunosuppressive therapy such as stem cell transplantation or rituximab therapy. |
Test with HBsAg and in some cases also with anti-HBc. |